Each track is a timeline of real events — lab results, roadmap updates, plan markers. So you can see what already happened and what is still a promise.
Lilly's in vivo gene-editing therapy achieved 62% LDL cholesterol reduction in early trials. This track monitors whether durable LDL reduction (≥50%) at 12 months or beyond is demonstrated in clinical data released by end of 2026.
Intellia's NTLA-2002, the first in vivo CRISPR therapy to clear Phase 3 trials, is positioned to receive FDA approval within 18 months, opening the pathway for in-body gene editing as a clinical standard.
A new retron-based system from UT Austin closes CRISPR's biggest blind spot, correcting multiple disease mutations.
Lilly's in vivo gene-editing therapy achieves 62% LDL cholesterol reduction in human trial, advancing non-invasive gene therapy approaches
Perovskite solar cells have achieved lab efficiency of 24.3%, but module-scale (>100 cm²) remains a hurdle. This track monitors whether the new 10-minute vacuum process technology achieves certified module efficiency above 20%.
DNA-based nanostructure vaccine platforms like DoriVac aim to outperform mRNA vaccines and enter human clinical trials by end of 2027, addressing cold-chain logistics and immunity durability.
DoriVac, a DNA-based nanostructure platform, aims to overcome mRNA vaccine limitations with improved immunity and cold-chain logistics.
Revolution Medicines reported practice-changing results targeting KRAS mutations in pancreatic cancer — a target long considered undruggable. FDA approval is expected within 24 months.
After a decade of failed trials, cardiac gene therapy programs are rebounding with new treatments targeting heart failure. This track monitors whether at least one program reports positive Phase 3 efficacy data by end of 2028.
Heart failure gene therapy is back with new treatments targeting heart failure after a decade of high-profile stumbles.
Cas12a2, a lesser-known CRISPR protein, destroys entire targeted cells on command — a fundamentally different weapon against cancer than DNA editing. Track monitors progression from lab discovery to first human clinical trial.
GSK's experimental hepatitis B drug achieving a functional cure rate of roughly 20% targets regulatory approval. This would represent a breakthrough in a field where current treatments almost never cure patients.
Private fusion companies demonstrate net electricity generation and grid interconnection before 2035, with Commonwealth Fusion Systems and others meeting grid connection requirements.
Which AGI definitions count as passed today, which not?
Bar exam, GRE, AP tests in the top percentile; but no open real-world test.
First models with significant lift, still far from the 85% threshold.
Tracking every verified Q>1 result on the path to commercial fusion energy.
First lab-confirmed net energy gain over a few nanoseconds.
Reproducibility confirmed; still far from a power plant.
Commonwealth Fusion and TAE Technologies announce demonstration plants for 2027.
Commonwealth Fusion Systems has filed a formal grid interconnection request with PJM — the first company to reach this milestone.
